);
Contáctanos

Etiqueta: Study

 

Publicado el
LinkedIn Post 1
July 2025

Fertiga at the 41st ESHRE Annual Meeting in Paris, France

Fertiga, in collaboration with Brussels IVF and Merck KGaA, Darmstadt, Germany, has announced ground-breaking results from the AURORA-REC study on gene expression in ICSI patients treated with r-hFSH or r-hFSH & r-hLH. During AURORA-REC study we evaluated the differences in cumulus cell gene expression between two types of ovarian stimulation and proved that gene-based algorithms can predict live birth in these patient groups:

  • the accuracy achieved for women stimulated with r-hFSH was 69%
  • the accuracy achieved for women stimulated with r-hFSH & r-hLH was 88%

Publicado el
July 2025

Fertiga teams up with Fertilab Barcelona in AURORA-Donor study

Suppressing the pituitary gland is essential during ovarian stimulation. Traditionally done via daily GnRH-antagonist injections, this study compared that approach to an alternative: using oral progesterone (Medroxyprogesterone). The key takeaways from the AURORA-Donor study so far:

  1. Both protocols are equally effective in egg maturation, fertilization, blastocyst development, and genetic quality (euploidy).
  2. No significant difference in hormonal levels or stimulation duration, but the progesterone protocol is:
  • 💰 40x more cost-efficient
  • 💊 More patient-friendly (oral vs. daily injections)
  • 🧑‍⚕️ Easier for clinics to manage.

The next step? Exploring gene expression in cumulus cells to better predict outcomes like live birth – stay tuned for more from the AURORA-Donor study!

Publicado el
LinkedIn Post 1
February 2024

We have been published in PLOS One!

Can we use a method that “scores” eggs based on the cells surrounding them (called cumulus cells) to pick the ones most likely to lead to a successful pregnancy? This approach can help reduce the number of embryos we need to grow in the lab and limit extra embryos being frozen.

In countries where freezing embryos is restricted, analyzing these surrounding cells allows us to focus only on the eggs with the best potential. This can reduce the chance of twins, lower the lab workload, and improve overall success rates, because less promising eggs are not processed unnecessarily.

💡Learn how our Aurora Test on cumulus cells can revolutionize embryo generation in countries with legal restrictions.

Publicado el
LinkedIn Post 1
February 2021

We have been published in Reproductive Biology and Endocrinology!

Non-invasive oocyte quality scoring, based on cumulus gene expression analysis, in combination with morphology scoring, can increase the clinical pregnancy (CPR) and live birth rates (LBR) in Day 3 eSET (elective single embryo transfer) ICSI patients. This was first investigated in a pilot study and is now confirmed in a large patient cohort of 633 patients. It was investigated whether CPR, LBR and time-to-pregnancy could be improved by analyzing the gene expression profile of three predictive genes in the cumulus cells, compared to patients with morphology-based embryo selection only.

💡The results of our study proved that:

  • the clinical pregnancy rate (CPR) was 61% in the Aurora test arm (n = 113) compared to 29% in the control arm (n = 520,  p < 0.0001).
  • the live birth rate (LBR) in the Aurora test arm (50%) was significantly higher than in the control arm (27%, p < 0.0001).
  • the time-to-pregnancy was significantly shortened by 3 transfer cycles independent of the number of embryos available on Day 3 (Kaplan-Meier, p < 0.0001).